Skip to main content
Erschienen in: Der Hautarzt 3/2012

01.03.2012 | Leitthema

Komorbiditäten und Psoriasis

Konsequenzen für die Praxis

verfasst von: Dr. S. Gerdes, U. Mrowietz

Erschienen in: Die Dermatologie | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Psoriasis ist eine genetisch determinierte, chronisch entzündliche Systemerkrankung. Neben charakteristischen Hautmanifestationen treten insbesondere bei mittelschwer bis schwer betroffenen Patienten andere Erkrankungen gehäuft auf. Diese begleitend auftretenden Erkrankungen werden als Komorbiditäten bezeichnet. Metabolische Erkrankungen (wie z. B. Diabetes mellitus, Insulinresistenz, Fettstoffwechselstörungen, meist auf der Grundlage einer Adipositas) und kardiovaskuläre Erkrankungen (wie z. B. arterieller Hypertonus, koronare Herzkrankheit, Myokardinfarkt und Apoplex) sind dabei von besonderer Bedeutung, da sie auch die Mortalität der Patienten beeinflussen können. Aber auch psychiatrische Erkrankungen sind bei Psoriasispatienten häufig und beeinflussen das Therapiemanagement. Der Dermatologe ist in den meisten Fällen der erste Ansprechpartner von Psoriasispatienten und somit die Schlüsselfigur im Therapiemanagement. Er ist dabei auch für die Früherkennung und Therapiesteuerung von Komorbiditäten mitverantwortlich. Die von ihm durchgeführte antipsoriatische Therapie muss mit den vorliegenden Komorbiditäten und deren medikamentösen Therapien abgestimmt werden. Der folgende Beitrag stellt den aktuellen Wissensstand über die psoriatischen Komorbiditäten und ihre Konsequenzen für die Praxis dar.
Literatur
1.
Zurück zum Zitat Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645PubMedCrossRef Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645PubMedCrossRef
2.
Zurück zum Zitat Armstrong AW, Armstrong EJ, Fuller EN et al (2011) Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. Br J Dermatol 165(6):1162–1168PubMedCrossRef Armstrong AW, Armstrong EJ, Fuller EN et al (2011) Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. Br J Dermatol 165(6):1162–1168PubMedCrossRef
3.
Zurück zum Zitat Armstrong AW, Voyles SV, Armstrong EJ et al (2011) A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol 20:544–549PubMedCrossRef Armstrong AW, Voyles SV, Armstrong EJ et al (2011) A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol 20:544–549PubMedCrossRef
4.
Zurück zum Zitat Augustin M, Glaeske G, Radtke MA et al (2010) Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 162:633–636PubMedCrossRef Augustin M, Glaeske G, Radtke MA et al (2010) Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 162:633–636PubMedCrossRef
5.
Zurück zum Zitat Boehncke S, Fichtlscherer S, Salgo R et al (2011) Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res 303:381–388PubMedCrossRef Boehncke S, Fichtlscherer S, Salgo R et al (2011) Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res 303:381–388PubMedCrossRef
6.
Zurück zum Zitat Boehncke S, Thaci D, Beschmann H et al (2007) Psoriasis patients show signs of insulin resistance. Br J Dermatol 157:1249–1251PubMedCrossRef Boehncke S, Thaci D, Beschmann H et al (2007) Psoriasis patients show signs of insulin resistance. Br J Dermatol 157:1249–1251PubMedCrossRef
7.
Zurück zum Zitat Boehncke WH, Boehncke S, Tobin AM, Kirby B (2011b) The „psoriatic march“: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 20:303–307PubMedCrossRef Boehncke WH, Boehncke S, Tobin AM, Kirby B (2011b) The „psoriatic march“: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 20:303–307PubMedCrossRef
8.
Zurück zum Zitat Boehncke WH, Buerger C, Boehncke S (2009) Co-morbidities in psoriasis vulgaris. Hautarzt 60:116–121PubMedCrossRef Boehncke WH, Buerger C, Boehncke S (2009) Co-morbidities in psoriasis vulgaris. Hautarzt 60:116–121PubMedCrossRef
9.
Zurück zum Zitat Bremmer S, Van Voorhees AS, Hsu S et al (2010) Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 63:1058–1069PubMedCrossRef Bremmer S, Van Voorhees AS, Hsu S et al (2010) Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 63:1058–1069PubMedCrossRef
10.
Zurück zum Zitat Cugno M, Ingegnoli F, Gualtierotti R, Fantini F (2010) Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis. Curr Vasc Pharmacol 8:285–292PubMedCrossRef Cugno M, Ingegnoli F, Gualtierotti R, Fantini F (2010) Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis. Curr Vasc Pharmacol 8:285–292PubMedCrossRef
11.
Zurück zum Zitat Eckel RH, Alberti KG, Grundy SM, Zimmet PZ (2010) The metabolic syndrome. Lancet 375:181–183PubMedCrossRef Eckel RH, Alberti KG, Grundy SM, Zimmet PZ (2010) The metabolic syndrome. Lancet 375:181–183PubMedCrossRef
12.
Zurück zum Zitat Fortes C, Mastroeni S, Leffondre K et al (2005) Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 141:1580–1584PubMedCrossRef Fortes C, Mastroeni S, Leffondre K et al (2005) Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 141:1580–1584PubMedCrossRef
13.
Zurück zum Zitat Gelfand JM, Neimann AL, Shin DB et al (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741PubMedCrossRef Gelfand JM, Neimann AL, Shin DB et al (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741PubMedCrossRef
14.
Zurück zum Zitat Gerdes S, Mrowietz U (2009) Impact of comorbidities on the management of psoriasis. Curr Probl Dermatol 38:21–36PubMedCrossRef Gerdes S, Mrowietz U (2009) Impact of comorbidities on the management of psoriasis. Curr Probl Dermatol 38:21–36PubMedCrossRef
15.
Zurück zum Zitat Gerdes S, Rostami-Yazdi M, Mrowietz U (2011) Adipokines and psoriasis. Exp Dermatol 20:81–87PubMedCrossRef Gerdes S, Rostami-Yazdi M, Mrowietz U (2011) Adipokines and psoriasis. Exp Dermatol 20:81–87PubMedCrossRef
16.
Zurück zum Zitat Gerdes S, Zahl VA, Knopf H et al (2008) Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 159:1116–1123PubMed Gerdes S, Zahl VA, Knopf H et al (2008) Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 159:1116–1123PubMed
17.
Zurück zum Zitat Gerdes S, Zahl VA, Weichenthal M, Mrowietz U (2010) Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology 220:38–43PubMedCrossRef Gerdes S, Zahl VA, Weichenthal M, Mrowietz U (2010) Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology 220:38–43PubMedCrossRef
18.
Zurück zum Zitat Gisondi P, Del GM, Di FV et al (2008) Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 88:1242–1247PubMed Gisondi P, Del GM, Di FV et al (2008) Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 88:1242–1247PubMed
19.
Zurück zum Zitat Gisondi P, Farina S, Giordano MV, Girolomoni G (2010) Usefulness of the framingham risk score in patients with chronic psoriasis. Am J Cardiol 106:1754–1757PubMedCrossRef Gisondi P, Farina S, Giordano MV, Girolomoni G (2010) Usefulness of the framingham risk score in patients with chronic psoriasis. Am J Cardiol 106:1754–1757PubMedCrossRef
20.
Zurück zum Zitat Han C, Lofland JH, Zhao N, Schenkel B (2011) Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol 10:843–850PubMed Han C, Lofland JH, Zhao N, Schenkel B (2011) Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol 10:843–850PubMed
21.
Zurück zum Zitat Henseler T, Christophers E (1995) Disease concomitance in psoriasis. J Am Acad Dermatol 32:982–986PubMedCrossRef Henseler T, Christophers E (1995) Disease concomitance in psoriasis. J Am Acad Dermatol 32:982–986PubMedCrossRef
22.
Zurück zum Zitat Hossler EW, Maroon MS, Mowad CM (2011) Gastric bypass surgery improves psoriasis. J Am Acad Dermatol 65:198–200PubMedCrossRef Hossler EW, Maroon MS, Mowad CM (2011) Gastric bypass surgery improves psoriasis. J Am Acad Dermatol 65:198–200PubMedCrossRef
23.
Zurück zum Zitat Jin Y, Yang S, Zhang F et al (2009) Combined effects of HLA-Cw6 and cigarette smoking in psoriasis vulgaris: a hospital-based case-control study in China. J Eur Acad Dermatol Venereol 23:132–137PubMedCrossRef Jin Y, Yang S, Zhang F et al (2009) Combined effects of HLA-Cw6 and cigarette smoking in psoriasis vulgaris: a hospital-based case-control study in China. J Eur Acad Dermatol Venereol 23:132–137PubMedCrossRef
24.
Zurück zum Zitat Jin Y, Zhang F, Yang S et al (2008) Combined effects of HLA-Cw6, body mass index and waist-hip ratio on psoriasis vulgaris in Chinese Han population. J Dermatol Sci 52:123–129PubMedCrossRef Jin Y, Zhang F, Yang S et al (2008) Combined effects of HLA-Cw6, body mass index and waist-hip ratio on psoriasis vulgaris in Chinese Han population. J Dermatol Sci 52:123–129PubMedCrossRef
25.
Zurück zum Zitat Kannan S, Heller MM, Lee ES, Koo JY (2011) The role of tumor necrosis factor-alpha and other cytokines in depression: what dermatologists should know. J Dermatolog Treat [Epub ahead of print] Kannan S, Heller MM, Lee ES, Koo JY (2011) The role of tumor necrosis factor-alpha and other cytokines in depression: what dermatologists should know. J Dermatolog Treat [Epub ahead of print]
26.
Zurück zum Zitat Kirby B, Richards HL, Mason DL et al (2008) Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol 158:138–140PubMed Kirby B, Richards HL, Mason DL et al (2008) Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol 158:138–140PubMed
27.
Zurück zum Zitat McAleer MA, Mason DL, Cunningham S et al (2001) Alcohol misuse in patients with psoriasis: identification and relationship to disease severity and psychological distress. Br J Dermatol 164:1256–1261CrossRef McAleer MA, Mason DL, Cunningham S et al (2001) Alcohol misuse in patients with psoriasis: identification and relationship to disease severity and psychological distress. Br J Dermatol 164:1256–1261CrossRef
28.
Zurück zum Zitat Mehta NN, Azfar RS, Shin DB et al (2010) Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 31:1000–1006PubMedCrossRef Mehta NN, Azfar RS, Shin DB et al (2010) Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 31:1000–1006PubMedCrossRef
29.
Zurück zum Zitat Mehta NN, Yu Y, Pinnelas R et al (2011) Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 124:775–776PubMed Mehta NN, Yu Y, Pinnelas R et al (2011) Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 124:775–776PubMed
30.
Zurück zum Zitat Naldi L, Chatenoud L, Linder D et al (2005) Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125:61–67PubMedCrossRef Naldi L, Chatenoud L, Linder D et al (2005) Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125:61–67PubMedCrossRef
32.
Zurück zum Zitat Paller AS, Siegfried EC, Langley RG et al (2008) Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 358:241–251PubMedCrossRef Paller AS, Siegfried EC, Langley RG et al (2008) Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 358:241–251PubMedCrossRef
33.
Zurück zum Zitat Patel RV, Shelling ML, Prodanovich S et al (2011) Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med 26:1036–1049PubMedCrossRef Patel RV, Shelling ML, Prodanovich S et al (2011) Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med 26:1036–1049PubMedCrossRef
34.
Zurück zum Zitat Prodanovich S, Ma F, Taylor JR et al (2005) Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52:262–267PubMedCrossRef Prodanovich S, Ma F, Taylor JR et al (2005) Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52:262–267PubMedCrossRef
35.
Zurück zum Zitat Puig L (2011) Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 25:1007–1011PubMedCrossRef Puig L (2011) Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 25:1007–1011PubMedCrossRef
36.
Zurück zum Zitat Reaven GM (2011) The metabolic syndrome: time to get off the merry-go-round? J Intern Med 269:127–136PubMedCrossRef Reaven GM (2011) The metabolic syndrome: time to get off the merry-go-round? J Intern Med 269:127–136PubMedCrossRef
37.
Zurück zum Zitat Reich K, Kruger K, Mossner R, Augustin M (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160:1040–1047PubMedCrossRef Reich K, Kruger K, Mossner R, Augustin M (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160:1040–1047PubMedCrossRef
38.
Zurück zum Zitat Schmitt JM, Ford DE (2007) Role of depression in quality of life for patients with psoriasis. Dermatology 215:17–27PubMedCrossRef Schmitt JM, Ford DE (2007) Role of depression in quality of life for patients with psoriasis. Dermatology 215:17–27PubMedCrossRef
39.
Zurück zum Zitat Setty AR, Curhan G, Choi HK (2007) Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses‘ Health Study II. Arch Intern Med 167:1670–1675PubMedCrossRef Setty AR, Curhan G, Choi HK (2007) Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses‘ Health Study II. Arch Intern Med 167:1670–1675PubMedCrossRef
40.
Zurück zum Zitat Setty AR, Curhan G, Choi HK (2007) Smoking and the risk of psoriasis in women: Nurses‘ Health Study II. Am J Med 120:953–959PubMedCrossRef Setty AR, Curhan G, Choi HK (2007) Smoking and the risk of psoriasis in women: Nurses‘ Health Study II. Am J Med 120:953–959PubMedCrossRef
41.
Zurück zum Zitat Shelton RC, Miller AH (2010) Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression. Prog Neurobiol 91:275–299PubMedCrossRef Shelton RC, Miller AH (2010) Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression. Prog Neurobiol 91:275–299PubMedCrossRef
42.
Zurück zum Zitat Wolf N, Quaranta M, Prescott NJ et al (2008) Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 45:114–116PubMedCrossRef Wolf N, Quaranta M, Prescott NJ et al (2008) Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 45:114–116PubMedCrossRef
43.
Zurück zum Zitat Wormser D, Kaptoge S, Di AE et al (2011) Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 377:1085–1095PubMed Wormser D, Kaptoge S, Di AE et al (2011) Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 377:1085–1095PubMed
44.
Zurück zum Zitat Reich K, Langley RG, Lebwohl M et al (2011) Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 164:862–872PubMedCrossRef Reich K, Langley RG, Lebwohl M et al (2011) Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 164:862–872PubMedCrossRef
45.
Zurück zum Zitat Mrowietz U, Kragballe K, Reich K et al (2011) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 303:1–11PubMedCrossRef Mrowietz U, Kragballe K, Reich K et al (2011) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 303:1–11PubMedCrossRef
Metadaten
Titel
Komorbiditäten und Psoriasis
Konsequenzen für die Praxis
verfasst von
Dr. S. Gerdes
U. Mrowietz
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
Die Dermatologie / Ausgabe 3/2012
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI
https://doi.org/10.1007/s00105-011-2230-x

Weitere Artikel der Ausgabe 3/2012

Der Hautarzt 3/2012 Zur Ausgabe

Einführung zum Thema

Psoriasis

CME Weiterbildung · Zertifizierte Fortbildung

Kutane Leishmaniasis als Reisedermatose

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.